Table TDI-25 part (i). Polydrug use among all clients entering outpatient treatment, for countries supplying data for 2003: the combination of cannabis, opiates, cocaine or other stimulants as primary drug type with a secondary drug. All clients with cannabis as primary drug: numbers reporting the stated drug as secondary

Country

Opiates

Cocaine

Other stimulants

Hypnotics, sedatives

Hallucinogens

Volatile inhalants

Cannabis

Alcohol

Others

Total

Czech Republic

22

3

123

3

33

17

7

23

7

238

Denmark

 

 

 

 

 

5

 

290

30

325

Germany

 

 

 

 

 

33

8438

1941

84

10496

Greece

42

35

40

29

20

9

2

10

6

193

Cyprus

3

 

 

 

 

 

 

4

 

7

Latvia

 

 

1

 

 

1

1

1

 

4

Luxembourg

 

 

 

 

 

 

 

6

 

6

Hungary

13

7

155

11

23

18

 

201

12

440

Malta

 

17

 

 

 

 

 

 

13

30

Netherlands

15

220

137

15

10

0

0

405

19

821

Slovenia

9

7

47

 

17

11   23

 1

115

Slovakia

19

 

23

5

1

1

 

40

 

89

Finland

22

2

125

38

1

1

 

186

4

379

Sweden

25

9

140

61

11

1

 

59

7

313

Bulgaria

2

 

1

 

 

 

 

 

0

3

Total

172

300

792

162

116

97

8448

3189

183

13459

Notes:

Data on secondary drug use are only collected among all treatment clients and not separately for new treatment clients.

Opiates include: heroin, methadone, other opiates; Cocaine includes: Cocaine CIH, crack cocaine; Stimulants include: amphetamines, MDMA and derivates, other stimulants: Cannabis can include herb or resin. For each client up to four secondary drugs can be reported.

A number of the clients report using the same drug both as primary and secondary drug, particulary for cannabis. Clients may report using different sub-types of the same substance, as defined in the TDI Protocol for the drugs categories. The greater part of clients using cannabis both as primary and secondary drug comes from Germany.

Source:

2004 Reitox national reports – see [Table TDI-19]

Data filter | tditab25a-en.xml